Skip to main content
SpringerLink
Log in

Update Rheumatologie — Teil II

Stand und Perspektiven der Pharmakotherapie chronischer Arthritiden

  • Update
  • Published:
Medizinische Klinik Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur NSAID

  1. Blum AL, Bolten WW, Labenz J, et al. Therapie und Prävention des ASS- und NSAR-Ulkus. Dtsch Ärztebl 1998;95:348–54.

    Google Scholar 

  2. Brune K, Hinz B. Selektive Cyclooxygenase-2-Hemmer: Glaube, Hoffnung, Realität. Aktuel Rheumatol 1998;23:1–5.

    Article  Google Scholar 

  3. Brune K, Hinz B.: Zum aktuellen Stand der Zyklooxygenaseforschung. Dtsch Ärztebl 1998;95:343–6.

    Google Scholar 

  4. Brune K, Glatt M, Graf P. Mechanism of action of inflammatory drugs. Gen Pharmacol 1976;7:27–33.

    PubMed  CAS  Google Scholar 

  5. Frölich JC. Pharmakologische Wirkungen von antiphlogistischen Substanzen auf den Knorpel. Z Rheumatol 1998;57:185.

    Article  Google Scholar 

  6. Fu JY, Masferrer JL, Seibert K, et al. The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J Biol Chem 1990;265:16737–40.

    PubMed  CAS  Google Scholar 

  7. Geis GS, Stead H, Morand S, et al. Efficacy and safety of celecoxib, a specific Cox-2 inhibitor in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl: 1699.abstract.

    Google Scholar 

  8. Gonzales E, de la Cruz C, de Nicola’s R. Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agent Actions 1994;41:171–8.

    Article  Google Scholar 

  9. Herschman HR. Prostaglandin-Synthase 2. Biochim Biophys Acta 1996;1299:125–40.

    PubMed  Google Scholar 

  10. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with Misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727–34.

    Article  PubMed  CAS  Google Scholar 

  11. Hubbard RC, Koepp RJ, Yu S, et al. SC-58635 (Celecoxib), a novel Cox-2 selctive inhibitor, is effective as a treatment for osteoarthritis (OA) in a short-term pilot study. Arthritis Rheum 1996;39:Suppl:1188.abstract.

    Google Scholar 

  12. Martel-Pelletier J, Cloutier J-M, Pelletier J-P. Effects of aceclofenac and Ddiclofenac on synovial inflammatory factor in human osteoarthritis. Clin Drug Invest 1997;14:226–32.

    Article  CAS  Google Scholar 

  13. Sano H, Hashiramoto A, Yamada R, et al. Treatment of rheumatoid arthritis and rat adjuvant-induced arthritis by cyclooxygenase-2 antisense through induction of apoptosis. Arthritis Rheum 1998;41:Suppl:772.abstract.

    Google Scholar 

  14. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase-2 inhibitor. Arthritis Rheum 1998;41:1591–602.

    Article  PubMed  CAS  Google Scholar 

  15. Stichenroth D, Zeidler H, Frölich J. Neue nichtsteroidale Antirheumatika: Selektive Hemmstoffe der induzierbaren Cyclooxygenase. Med Klin 1998;93:407–15.

    Article  Google Scholar 

  16. Tugwell P, Ortiz Z, Griffith B. Rheumatoid arthritis: Emerging evidence for the benefits of early and aggressive therapy. Dis Managem Hlth Outcomes 1997;3:141–53.

    Article  Google Scholar 

  17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 1971;231 232–5.

    PubMed  CAS  Google Scholar 

  18. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with Rranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:719–26.

    Article  PubMed  CAS  Google Scholar 

Literatur Glucocorticoide

  1. American College of Rheumatology Task Force on Osteoporosis Guidelines: Recommendations of the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791–01.

    Article  Google Scholar 

  2. Arvidson NG, Gudbjornsson B, Larsson A, et al. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997;56:27–31.

    Article  PubMed  CAS  Google Scholar 

  3. Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids. Inhibition of NF-kB activity through induction of IkBa synthesis. Science 1995;270:286–90.

    Article  PubMed  CAS  Google Scholar 

  4. Bamberger CM, Schulte HM. Wirkungsmechanismus der Glucocorticoide. Internist (Berlin) 1997;38:366–70.

    CAS  Google Scholar 

  5. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200–57.

    PubMed  CAS  Google Scholar 

  6. Boumpas DT, Paliogianni F, Anastassiou ED, et al. Glucocorticosteroid action of the immune system: molecular and cellular aspects. Clin Exp Rheumatol 1991; 9:413–23.

    PubMed  CAS  Google Scholar 

  7. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961–8.

    PubMed  CAS  Google Scholar 

  8. Civitelli R. The role of vitamin D metabolites in the treatment of osteoporosis. Calcif Tissue Int 1995;57:409–14.

    Article  PubMed  CAS  Google Scholar 

  9. Cortet B, Flipo RM, Blanckaert F, et al. Evalution of bone mineral density in patients with rheumatoid arthritis. Influence of disease activity and glucocorticoid therapy. Rev Rhum Engl Ed 1997;64:451–8.

    PubMed  CAS  Google Scholar 

  10. Crofford LJ, Kalogeras KT, Mastorakos G, et al. Circadian relationship between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones. Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997;82:1279–83.

    Article  PubMed  CAS  Google Scholar 

  11. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996;35:309–22.

    Article  PubMed  CAS  Google Scholar 

  12. Dequeker J, Maenaut K, Verwilghen J, et al. Osteoporosis in rheumatoid arthritis. Clin Exp Rheumatol 1995;13:Suppl 12:S21–6.

    Google Scholar 

  13. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum 1996;39:396–402.

    Article  PubMed  CAS  Google Scholar 

  14. Gough AK, Lilley J, Eyre S, et al. Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23–7.

    Article  PubMed  CAS  Google Scholar 

  15. Goulding NJ, Godolphin JL, Sharland PR, et al. Anti-inflammatory lipocortin 1 is produced by peripheral blood leucocytes in response to intravenous hydrocortisone. Lancet 1990;335:1416–9.

    Article  PubMed  CAS  Google Scholar 

  16. Goulding NJ. Corticosteroids — a case of mistaken identity? Br J Rheumatol 1998;37:477–80.

    Article  PubMed  CAS  Google Scholar 

  17. Gudbjornsson B, Skogseid B, Oberg K, et al. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. J Rheumatol 1996;23:596–602.

    PubMed  CAS  Google Scholar 

  18. Joyce DA, Steer JH, Abraham LJ. Glucocorticoid modulation of human monocyte/macrophage function: control of TNF-a secretion. Inflamm Res 1997;46:447–51.

    Article  PubMed  CAS  Google Scholar 

  19. Kirwan JR, ARC Low-dose Glucocorticoid Study Group. The effect of glucocorticoid and joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142–6.

    Article  PubMed  CAS  Google Scholar 

  20. Kirwan JR, Kim KK. Low dose corticosteroids in early rheumatoid arthritis: Can these drugs slow disease progression? Drugs Aging 1996;8:157–61.

    Article  PubMed  CAS  Google Scholar 

  21. Masi AT, Chrousos GP. Dilemmas of low dosage glucocorticoid treatment in rheumatoid arthritis: considerations of timing. Ann Rheum Dis 1997;56:1–4.

    Article  PubMed  CAS  Google Scholar 

  22. McGill PE, Kerr H, Stirling A. Effect of cyclical etidronate on BMD insteroid treated RA. Bone 1997;20:Suppl:S99.

    Google Scholar 

  23. Oelzner P, Müller A, Deschner F, et al. Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193–8.

    Article  PubMed  CAS  Google Scholar 

  24. Oelzner P, Hein G. Entzündung und Knochenstoffwechsel bei rheumatoider Arthritis — Pathogenetische Gesichtspunkte und therapeutische Möglichkeiten. Med Klin 1997;92:607–14.

    Article  CAS  Google Scholar 

  25. Peel NF, Moore DJ, Barrington NA, et al. Risk of vertebral fracture and relationship to bone mineral density in steroid treated rheumatoid arthritis. Ann Rheum Dis 1995;54:801–6.

    Article  PubMed  CAS  Google Scholar 

  26. Ringe JD. Generalisierte Osteoporose bei chronischer Polyarthritis — Pathomechanismen und Behandlungsansätze. Z Rheumatol 1996;55:149–57.

    PubMed  CAS  Google Scholar 

  27. Saag KG, Criswell LA, Sems KM, et al. Low dose corticosteroids in rheumatoid arthritis. A meta-analysis of their moderate-term effectiveness. Arthritis Rheum 1996; 39:1818–25.

    Article  PubMed  CAS  Google Scholar 

  28. Sambrook P, Birmingham J, Kelly, P, et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328:1747–52.

    Article  PubMed  CAS  Google Scholar 

  29. Sambrook PN, Jones J. Corticosteroid osteoporosis. Br J Rheumatol 1995;34:8–12.

    Article  PubMed  CAS  Google Scholar 

  30. Scheinman RI, PC Cogswell, Lofquist AK, et al. Role of transcriptional activation of IkBa in mediation of immunosuppression by glucocorticoids. Science 1995;270: 283–6.

    Article  PubMed  CAS  Google Scholar 

  31. Stichtenoth DO, Frolich JC. Nitric oxide and inflammatory joint diseases. Br J Rheumatol 1998;37:246–57.

    Article  PubMed  CAS  Google Scholar 

  32. Tarbadel Y, Duchateau J, Schmartz D, et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. Surgery 1996;119:76–80.

    Article  Google Scholar 

  33. Verstraeten A, Dequeker J, Nijs J, et al. Prevention of postmenopausal bone loss in rheumatoid arthritis patients. A two year prospective study. Clin Exp Rheumatol 1989;7:351–8.

    PubMed  CAS  Google Scholar 

Literatur Basisterapie

  1. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996;39:713–22.

    Article  Google Scholar 

  2. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a doubleblind placebo-controlled study. Br J Rheumatol 1996;35:1142–9.

    Article  PubMed  CAS  Google Scholar 

  3. Burkhardt H, Kalden J. Xenobiotic immunosuppressive agents: therapeutic effects in animal models of autoimmune diseases. Rheumatol Int 1997;17:85–90.

    Article  PubMed  CAS  Google Scholar 

  4. Chaudhuri K, Torley H, Madhok R. Cyclosporin. Br J Rheumatol 1997; 36:1016–21.

    Article  PubMed  CAS  Google Scholar 

  5. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter’s syndrome). Arthritis Rheum 1996; 39:2021–7.

    Article  PubMed  CAS  Google Scholar 

  6. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum 1996;39:2004–12.

    Article  PubMed  CAS  Google Scholar 

  7. Egsmose C, Hansen TM, Andersen LS, et al. Limitid effect of sulfasalzine treatment in reactive arthritis. A randomised double blind placebo controlled trial. Ann Rheum Dis 1997;56:32–6.

    Article  PubMed  CAS  Google Scholar 

  8. Flipo RM, Emery P, Scott DG, et al. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis. J Rheumatol 1998;25:1263–9.

    PubMed  CAS  Google Scholar 

  9. Fox RI. Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998;53:Suppl:20–6.

    CAS  Google Scholar 

  10. Jones G, Crotty M, Brooks P, The Psoriatic Arthritis Meta-Analysis Study Group. Psoriatic arthritis: A quantitative overview of therapeutic options. Br J Rheumatol 1997; 36:95–9.

    Article  PubMed  CAS  Google Scholar 

  11. Li E, Brooks P, Conaghan PC. Disease-modifying antirheumatic drugs. Curr Opin Rheumatol 1998; 10:159–68.

    Article  PubMed  CAS  Google Scholar 

  12. Lorenz HM, Geiler T, Kalden JR. Immunsuppressive Therapiemodalitäten bei chronischen Polyarthritiden. Internist (Berlin) 1997;38:532–40.

    Article  CAS  Google Scholar 

  13. Moreland LW, Fleischmann RM, for the Leflunomide RA Investigators Group and Strand V. Efficacy of lefluomide vs placebo vs methotrexate in early and late rheumatoid arthritis. Arthritis Rheum 1998;41:Suppl:S155.

    Article  Google Scholar 

  14. Olivieri I, Salvarani C, Cantini F, et al. Therapy with cyclosporin in psoriatic arthritis. Semin Arthritis Rheum 1997;27:36–43.

    Article  PubMed  CAS  Google Scholar 

  15. Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006–15.

    Article  PubMed  CAS  Google Scholar 

  16. Rau R, Furst DE, Menninger H, et al. Kombinationstherapie bei chronischer Polyarthritis. Z Rheumatol 1998;57:17–49.

    Article  PubMed  CAS  Google Scholar 

  17. Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators Group. J Rheumatol 1998;53:Suppl:27–32.

    CAS  Google Scholar 

  18. Schnülle P, van der Woude FJ Mycophenolat Mofetil im Vergleich zu anderen Immunsuppressiva. Internist (Berlin) 1998;39:879–86.

    Article  Google Scholar 

  19. Smolen JS, Kalden JR, Scott DL, et al. the European Leflunomide Study Group. Efficacy and safety of leflunomide compared with placebo and sulphasalzine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999;353:259–66.

    Article  PubMed  CAS  Google Scholar 

  20. Somerville MF, Scott DG. Neoral-new cyclosporin for old? Br J Rheumatol 1997;36:1113–5.

    Article  PubMed  CAS  Google Scholar 

  21. Stein CM, Pincus T, Yocum D, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum 1997;40:1843–51.

    Article  PubMed  CAS  Google Scholar 

  22. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995;333:137–41.

    Article  PubMed  CAS  Google Scholar 

  23. van den Borne BE, Landewe RB, Goei The HS, et al. Combination therapy in recent onset rheumatoid arthritis: a randomized double blind trial of the addition of low dose cyclosporine to patients treated with low dose chloroquine. J Rheumatol 1998;25:1493–8.

    PubMed  Google Scholar 

  24. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol 1998;37:612–9.

    Article  PubMed  CAS  Google Scholar 

  25. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: Comparison of low-dose cyclosporin and parenteral gold. Br J Rheumatol 1998; 37:874–82.

    Article  PubMed  CAS  Google Scholar 

  26. Zink A, Listing J, Gu F, et al., Modellverbund BMG-geförderter Rheumazentren. Rheumatologische Kerndokumentation in der BMG-geförderten Rheumazentren im Jahr 1995. Deutsches Rheuma-Forschungszentrum Berlin. Forschungsbereich Epidemiologie. Epi-Report No 6, Berlin, Juli 1997.

Literatur Antizytokintherapie

  1. Alsalameh S, Kalden JR, Burmester GR. Die Rolle von Zytokinen und Wachstumsfaktoren bei der rheumatoiden Gelenkdestruktion. Z Rheumatol 1991;50:347–59.

    PubMed  CAS  Google Scholar 

  2. Bresnihan B, on behalf of the collaborating investigators, Lookabaugh J, Witt K, Mukisic P. Treatment with recombinant human interleukin-1 receptor antagonist (rhulL-1ra) in rheumatoid arthritis: Results of a randomized double-blind, placebo-controlled multicenter study. Arthritis Rheum 1996;39:Suppl 9:73.

    Google Scholar 

  3. Burmester GR, Manger B, Kalden J. Immunpathogenese entzündlich-rheumatischer Erkrankungen. Dtsch Ärztebl 1995;92:1010–20.

    Google Scholar 

  4. Chu CQ, Field M, Feldmann M, et al. Localization of tumour necrosis factor a in synovial tissues and at the cartilage pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125–32.

    Article  PubMed  CAS  Google Scholar 

  5. Elliot MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor a. Arthritis Rheum 1993; 36:1681–90.

    Article  Google Scholar 

  6. Elliot MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105–10.

    Article  Google Scholar 

  7. Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996;8:195–200.

    Article  PubMed  CAS  Google Scholar 

  8. Kalden-Nemeth D, Grebmeier J, Antoni C, et al. NMR monitoring of rheumatoid arthritis patients receiving anti-TNF-alpha monoclonal antibody therapy. Rheumatol Int 1997;16:249–55.

    Article  PubMed  CAS  Google Scholar 

  9. Lorenz HM, Antoni C, Valerius T, et al. In vivo blockade of TNF-alpha by i. v. infusion of a chimeric, monoclonal TNF-alpha natibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996;156:1646–53.

    PubMed  CAS  Google Scholar 

  10. Maini RN. Monoclonal anti-TNFa antibody (cA2) in the treatment of rheumatoid arthritis. In: Feng PH, ed. Proc of the XIXth ILAR Congress of Rheumatology. Singapore: Communication Consultants, 1997:459–64.

  11. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552–63.

    Article  PubMed  CAS  Google Scholar 

  12. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141–7.

    Article  PubMed  CAS  Google Scholar 

  13. Rankin EC, Choy EH, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995;34:334–42.

    Article  PubMed  CAS  Google Scholar 

  14. Salfeld J, Kaymakçalan Z, Tracey D, et al. Generation of fully human anti-TNF antibody D2E7. Arthritis Rheum 1998; 41:S57.

    Google Scholar 

  15. Schattenkirchner M, Krüger, K, Sander O, et al. Efficacy and tolerability of weekly subcutaneous injections of the fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis — results of a phase I study. Arthritis Rheum 1998; 41:S57.

    Google Scholar 

  16. van de Putte L, van Riel P, den Broeder A, et al. A single dose placebo controlled phase I study of the fully human anti-TNF antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:S57.

    Google Scholar 

  17. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253–9.

    Article  PubMed  CAS  Google Scholar 

  18. Weinblatt ME, Moreland LW, Schiff MH, et al. Longterms and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75-Fc-fusion protein (TNF:Fc:ENBRELTM). Arthritis Rheum 1997; 40:S59.

    Google Scholar 

  19. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993;14:243–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Funktionsbereich Rheumatologie/Osteologie, Klinik für Innere Medizin IV, Friedrich-Schiller-Universität Jena, D-07740, Jena

    Gert Hein, Thorsten Eidner & Peter Oelzner

  2. Medizinische Klinik III und Institut für Klinische Immunologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen-Nürnberg, Deutschland

    Bernhard Manger

Authors
  1. Gert Hein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Eidner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Oelzner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bernhard Manger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gert Hein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hein, G., Eidner, T., Oelzner, P. et al. Update Rheumatologie — Teil II. Med Klin 94, 556–563 (1999). https://doi.org/10.1007/BF03044953

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03044953

Search

Navigation